|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
New Drugs Slow Metastatic Prostate Cancer
10/19/2005 5:11:46 PM
A drug used to treat advanced breast and lung cancers has been found to prolong the lives of men with advanced prostate cancer whose tumors don't respond to hormone therapy, according to two studies published on Wednesday.
But treatment with docetaxel, sold by Aventis under the brand name Taxotere, is not a cure. The men who received it only lived two months longer than patients who received the Amgen drug mitoxantrone.
The lead author of one of the studies, Daniel Petrylak of Columbia University, said the research shows "Taxotere is a new standard for the treatment of men with advanced prostate cancer" and the first drug to increase survival when hormone therapy doesn't work.
Prostate cancer kills about 29,900 men each year in the United States and more than 230,000 are diagnosed with it each year, according to the American Cancer Society.
Both studies were funded by Aventis, which is part of the Sanofi-Aventis Group, and published in the New England Journal of Medicine.
|
|
|
|
|
|
|
|
|
|
|